SYNTHESIS, BIOLOGICAL EVALUATION, MOLECULAR MODELING, AND DOCKING STUDIES OF CIPROFLOXACIN DERIVATIVES
Ciprofloxacin, a fluoroquinolone analogue has activity against a wide range of Gram-negative and Gram-positive microorganisms by inhibiting
the enzymes topoisomerase-II (DNA-gyrase) and topoisomerase-IV which are required for bacterial DNA replication, transcription, repair, and
recombination. A series of ciprofloxacin Schiff bases were synthesized (1a-j) via >C=N- linkage by reacting ciprofloxacin with various primary
amines through nucleophilic addition reaction in the presence of glacial acetic acid and were characterized on the basis of infrared, nuclear magnetic
resonance, mass spectrometry, and elemental analysis techniques. In the present investigation, we screened ciprofloxacin Schiff bases based on a
better Docking simulation with QRDR-A. The compound 1g, 1b and 1d resulted in a dock score of âˆ’154.82, âˆ’145.27 and âˆ’144.32 kcal.molâˆ’1 ranked
first, second, and third, respectively, and the compound 1g along with 1c, 1f, and 1j also interacted with Asp87. It was found that 1a, 1d, and 1e induced
marked influence on Gram-negative and Gram-positive antibacterial activity. The compound 1j shows potent antifungal activity against Aspergillus
niger and Candida albican. The compound 1g, shows an excellent anti-tubercular activity. The correlation between experimental data (minimum
inhibitory concentration) versus docking score displayed 0.93 r2, which suggests that parameters for docking simulation are good in reproducing
experimental orientation of these compounds. From the observed result, the analogs of ciprofloxacins are suggested to be potent inhibitors with
sufficient scope for further exploration.
Keywords: DNA-gyrase, Schiff bases, Docking, Molecular modeling.
Patrick GL. An Introduction to Medicinal Chemistry. 3rd ed. Oxford: Oxford University Press; 2005.
Stille W, Brodt HR, Groll A, Just- Nuebling G. Antibiotika-Therapie: Klinik und Praxis der Antiinfektioesen Therapie. 11th.ed. kompl. akt. u. erw. Aufl. Stuttgart: Schattauer; 2006. p. 11, 14.
Walsh C. Where will new antibiotics come from? Nat Rev Microbiol 2003;1:65-70.
Appelbaum PC, Hunter PA. The fluoroquinolone antibacterials: Past, present and future perspectives. Int J Antimicrob Agents 2000;16(1):5â€‘15.
LeBel M. Ciprofloxacin: Chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy 1988;8(1):3-33.
Dax SL. Antibacterial Chemotherapeutic Agents. London: Chapman & Hall; 1997. p. 1-37.
Zeiler HJ, Grohe K. The in vitro and in vivo activity of ciprofloxacin. Eur J Clin Microbiol 1984;3(4):339-43.
Kuhlmann J, Dalhoff A, Zeiler JJ. Quinolone Antibacterials. New York: Springer-Verlag; 1998.
Ronald AR, Low DE. Fluoroquinolone Antibiotics. Boston: Birkhauser; 2003.
Hooper DC, Rubinstein E. Quinolone Antimicrobial Agents. 3rd ed. Washington, DC: ASM Press; 2003.
Grosset JH. Treatment of tuberculosis in HIV infection. Tuber Lung Dis 1992;73:378-83.
Zurenko GE, Ford CW, Hutchinson DK, Brickner SJ, Barbachyn MR. Oxazolidinone antibacterial agents: Development of the clinical candidates eperezolid and linezolid. Expert Opin Investig Drugs 1997;6(2):151-8.
How to Cite
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.